Stifel reiterates Buy on Repligen stock, keeps $207 target
Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.
How this was made
The 30-second read
Why it matters
The earnings beat and higher price target provide a fresh catalyst that could attract buying interest.
Market read
The new earnings data and analyst target may drive short‑term price appreciation for RGEN.
What to watch
Margin and cost synergies from the Biolife acquisition are still uncertain and could affect future performance.
Background
Repligen reported record Q3 2026 revenue and earnings, driven by its Chromatography and Proteins segments, while Stifel reaffirmed its Buy stance.
Ticker impact
Stifel reiterated a Buy rating on Repligen, kept a $207 price target and highlighted strong Q3 2026 earnings that beat expectations.
likely upward pressure as investors price in the earnings beat and higher target.
The earnings beat and higher price target are fresh facts that can move the stock in the near term.
Market effects
Strong results may lift the broader biotech and life‑science tools sector.
Positive for US‑listed biotech stocks.
Limited to investors tracking US biotech equities.
Counterpoint
Some analysts remain cautious, maintaining a Hold rating despite the earnings beat.
Key entities
- companyRepligen Corporation
Biotech company reporting earnings and receiving analyst coverage.
- analystStifel
Equity research firm reiterating a Buy rating and $207 target.

